Teva Pharmaceuticals is trading 5.25% up at ILA 12,630.00, with buying continuing after the FDA’s October 9 approval of WELTRUZA, its once-monthly injectable schizophrenia treatment, during the October 12 session.

  • Shares were among the leading TA-35 gainers and reached a five-year high.
  • Teva also announced an R&D Day for November 11.